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ABSTRACT: 
OBJECT Giant cell tumors are a locally aggressive primary bone neoplasm of osteoclast-like 
cells.  These lesions largely occur in the epiphyses of long bones, but there have been rare 
reports of occurrence in the pelvis, spine, or skull. Of those located in the skull, involvement of 
the clivus has been rarely reported.  
METHODS We present a case of an 18-year-old presenting with a third nerve palsy, found to 
have a lytic lesion of the upper clivus that was primarily treated with endoscopic endonasal 
resection. Her third nerve palsy resolved post-operatively, and subsequent histopathologic 
analysis revealed a giant cell tumor (GCT).  6 month post-operative MRI revealed progression 
of residual disease for which she was treated with adjuvant Denosumab. This treatment resulted 
in a significant decrease in the tumor size. She subsequently underwent proton beam radiation. 
RESULTS At 1 year post surgery, the patient’s MRI remained stable after completing 
Denosumab and proton therapy. She was neurologically intact and had no issues from her 
treatment. 
CONCLUSIONS Denosumab has demonstrated anti-GCT efficacy. In combination with proton 
therapy, it has the potential to spare a young, vulnerable population from adverse long-term 
effects of traditional adjuvant radiation therapy. To the best of our knowledge, this is the first 
report of the use of Denosumab in the treatment of GCT of the clivus in the United States. 
INTRODUCTION: 
Giant cell tumors (GCT) are primary bone neoplasms that mainly affect young adults. These 
tumors are relatively rare and represent about 4.0-9.5% of all bone tumors1. While classically, 
GCTs are benign, they can be locally aggressive and rarely undergo malignant 
transformation2,3. Most GCTs present within the long bones of the extremities, such as the distal 
femur, proximal tibia, or distal radius; however, there have been rare reported cases involving 
the pelvis, spine, or skull1.  
The low incidence of skull base GCTs not only makes the definitive diagnosis more difficult, but 
also presents challenges as far as recommended treatments. There are no defined guidelines 
for the treatment of these lesions, but the mainstay of treatment has been gross total surgical 
resection and drilling of surrounding healthy bone2. Due to the challenging location of these 
tumors, however, complete resection is often not possible, which can result in residual or 
recurrent tumor. This dilemma highlights the importance of adjuvant therapy for GCTs1. 
Radiotherapy, with a dose of 45-60 Gy, has historically been used as adjuvant therapy in the 
treatment of GCTs. 1,3-6. Because these tumors typically present in young adults, the long-term 
side effects of radiation become more problematic in this patient population.  
Recent studies on GCTs of bone have shown that the secretion of receptor activator of nuclear 
factor kappa-B ligand (RANK-L) by osteoblast-like stromal cells stimulates the production of 
osteoclast-like giant cells. This up-regulation of osteoclast-like giant cells promote osteolysis1. 
Denosumab is a recently introduced monoclonal antibody that targets RANK-L to inhibit the 
osteolytic activation of these osteoclast-like cells, and has shown benefit for the treatment of 
GCTs of the long bones1. Additionally, there have been two reports of its use in the treatment of 
skull base GCTs1,7. We describe a case of adjuvant Denosumab therapy in combination with 
proton therapy for the treatment of a residual clival GCT. 
METHODS: 
An otherwise healthy 18-year-old female presented to our hospital with a 1-month history of 
diplopia and headaches. Physical examination revealed a partial right oculomotor nerve palsy 
presenting as ptosis, anisocoria without afferent pupillary defect, and lateral deviation of the 
pupil. There were no symptoms of pituitary abnormality and pituitary hormone labs were within 
normal limits. Computed tomography (CT) of the skull base showed a lytic lesion of the dorsum 
sella and the upper clivus, with an exophytic component into the sphenoid sinus (Fig 1A). 
Magnetic resonance imaging (MRI) showed a heterogeneously enhancing, hyperintense lesion 
in the upper clivus that displaced the sellar contents anteriorly and superiorly, extending toward 
the right cavernous sinus (Fig 1B and C).   
Due to concern that this represented a primary skull base tumor, resection was recommended 
via an expanded endonasal endoscopic approach. A routine endonasal approach to the sella 
and upper clivus was performed.  The tumor was curetted out of the bone until all observable 
soft tissue had been removed. The portion of the tumor in the sphenoid sinus was also removed 
and sent for frozen sectioning. The dura mater of the sella turcica and posterior fossa were 
identified and appeared grossly intact. Tumor was progressively resected until the dorsum sella 
was completely removed, which was confirmed with a 30 degree angled endoscope. The only 
remaining bony margin was located inferiorly and this was subsequently removed using a 360 
degree bone cutting tip on a Sonopet ultrasonic aspirator until solid, normal-appearing bone was 
identified. Following the completion of maximal resection, final inspection revealed no signs of 
cerebrospinal fluid leak. Histopathologic analysis confirmed the diagnosis of Giant Cell Tumor. 
Post-operatively, the patient did well. She was monitored in the ICU the night after surgery, and 
her head CT the following morning showed no acute findings. She was discharged home on 
post-operative day 1.   
At 2 month post-operative follow-up, her diplopia, ptosis and headaches had resolved.  Her right 
pupil remained 2mm larger than the left, but still briskly reactive. She had no other neurologic 
deficits.  Follow-up MRI at 3 months post-operatively revealed a small amount of residual tumor 
in her right cavernous sinus, as well as possible small progression posterior to this remnant (Fig 
1D and E). At this time, it was decided to conservatively watch the patient and have her return 
for another MRI in 3 months. At 6 months, post-operatively, her MRI showed further progression 
of her residual tumor (Figure 2A and B). This was most notable with posterior growth towards 
the pons.  As this residual tumor was determined to be unresectable, she was referred for 
adjuvant treatment with Denosumab. The patient underwent 24 cycles of Denosumab over the 
course of 5 months. She tolerated her treatment well without any serious side effects. 
MRI at 2 months after initiating Desonumab, showed a significant decrease in the sellar lesion 
with improvement in the compression of her pons (Figure 2C and D). Because she had shown 
signs of tumor growth prior to starting Desonumab, she was referred for proton beam radiation. 
The patient underwent 28 treatments at a dose of 50.51 DRBE over the course of 37 days, and 
then had 5 boost doses at 9.08 DRBE over a 5 day period. Repeat MRI 1 year out from her initial 
surgery showed a stable size in the lesion when compared to after she initiated Desonumab 
(Figure 2E and F). She continued to feel well and was neurologically intact 1 year after surgery.  
DISCUSSION: 
Giant cell tumors of bone are rare primary osseous neoplasms that usually affect the epiphyses 
of the long bones of the extremities, but can rarely affect areas of the axial skeleton such as the 
spine and skull1,8.  Overall, this lesion is more common in females, and usually occurs in the 
young adults. While generally considered a benign tumor, metastasis to the lungs can be seen 
in up to 5% of cases, and transformation to malignant sarcoma has been described1-3. The most 
common presenting symptoms for GCTs of the clivus are headache, diplopia, and cranial nerve 
palsies with normal endocrinologic function1. Our patient experienced a similar presentation.  
Recent studies on the pathophysiology of giant cell tumors of the bone have revealed that 
RANK-L secretion by osteoblast-like stromal cells is involved in the induction of osteoclast-like 
cell production, as well as stimulation of osteolytic activity 9. Gori et al. showed that 
undifferentiated marrow stromal cells with high levels of RANK-L support osteoclastogenesis 10. 
Because GCT’s are osteolytic tumors, inhibiting RANK activation with a RANK-L antibody, could 
prevent progression of disease. Denosumab, a new monoclonal antibody that targets RANK-L, 
has emerged as an effective chemotherapeutic treatment for residual skull base GCTs. This 
therapy has been approved in many countries and recent data suggests that it may even be 
able to serve as an alternative therapy in residual GCT’s1. As this is a novel therapy, optimal 
length of treatment has not been determined. However, it has been concluded that therapy 
administration should not exceed 2 years as long-term use of Denosumab appears to increase 
the risk of osteonecrosis of the jaw, bone fractures, and severe hypocalcemia in those with renal 
dysfunction1,7.  In the case of our patient, 24 cycles over the course of 5 months proved to be an 
effective treatment protocol as it decreased the size of her recurrent tumor. 
Currently, there are no definitive treatment recommendations for skull-base GCTs, but the 
mainstay is function-preserving surgery2. The ideal treatment for GCTs is complete resection 
with wide surgical margins; however, the location of skull-base GCTs can make this difficult7. 
Often, such tumors are treated with subtotal or partial resection with adjuvant therapy, which 
historically has been standard radiotherapy with a dose of 45-60 Gy1,3-6. Although radiotherapy 
has been used as adjuvant therapy in many cases, its potential risk and effectiveness are still 
areas of debate. Prior research has shown malignant transformation of GCT’s treated with 
standard radiation in up to 11% of cases 11,12. Due to the small number of these cases, the 
overall effectiveness of standard radiation is still unclear 1,3. Additionally, standard radiation in 
young individuals has many associated risks, including secondary malignancies, lymphedema, 
muscle atrophy and decreased joint motion13.  Because of these risks, proton therapy offers an 
alternative radiation option with lower systemic risks. Proton radiotherapy continues to show 
safety and effectiveness in treating tumors of the skull base, especially in younger patients 14-16. 
In the case of our patient, proton therapy was used due to her young age and with the hope of 
avoiding long-term complications.  
 
Complete resection of tumor with wide margins is the optimal treatment for GCTs of the clivus. 
Unfortunately, this is not possible in most cases due to their challenging location. The difficulty 
of complete resection and the high rate of recurrence, especially from incomplete resection, 
highlight the importance of adjuvant therapy in the treatment of these tumors. Although 
previously approved for post-menopausal osteoporosis, Denosumab received FDA approval in 
2013 to treat unresectable GCTs. The most recent data on the use of this adjuvant monoclonal 
antibody therapy is showing promise, but further investigating is necessary to show definitive 
benefit. 
 
 
CONCLUSION: 
Due to their challenging location, clival GCT’s are often unable to be completely resected, 
highlighting the need for adjuvant treatment options. Denosumab is an emerging 
chemotherapeutic treatment for residual Giant Cell Tumors. Further studies are needed to show 
the maximum benefit and appropriate treatment protocol for Denosumab in the treatment of 
GCTs of the clivus.  
Figure 1: Initial Head CT showing lytic lesion of the dorsum sella and upper clivus (A). 
Preoperative axial and sagittal MRI brain with contrast showing a heterogeneously enhancing, 
hyperintense lesion in the upper clivus (B and C). 3 month post-operative axial and sagittal MRI 
brain with contrast showing a small amount of residual tumor in her right cavernous sinus, as 
well as possible small progression posterior to this remnant (D and E). 
Figure 2: 6 month post-operative axial and sagittal brain MRI with contrast showing further 
progression of her residual tumor (A and B). Axial and sagittal brain MRI with contrast 2 months 
after initiating Denosumab therapy, which showed a significant decrease in the size of her 
residual tumor (C and D). 1 year post-operative brain MRI with contrast showing stable size of 
tumor since completing Denosumab therapy.  
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